<SEC-DOCUMENT>0001193125-23-050813.txt : 20230227
<SEC-HEADER>0001193125-23-050813.hdr.sgml : 20230227
<ACCEPTANCE-DATETIME>20230227162703
ACCESSION NUMBER:		0001193125-23-050813
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230221
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230227
DATE AS OF CHANGE:		20230227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		23675334

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d372195d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:txmd="http://www.therapeuticsmd.com/20230221" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-02-21_to_2023-02-21">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-02-21_to_2023-02-21">0000025743</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="txmd-20230221.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-02-21_to_2023-02-21"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-21</xbrli:startDate> <xbrli:endDate>2023-02-21</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-02-21_to_2023-02-21">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt:datemonthdayyearen">February&#160;21, 2023</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-02-21_to_2023-02-21">TherapeuticsMD, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-02-21_to_2023-02-21">001-00100</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-02-21_to_2023-02-21">87-0233535</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-02-21_to_2023-02-21">951 Yamato Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-02-21_to_2023-02-21">Suite 220</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-02-21_to_2023-02-21">Boca Raton</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-02-21_to_2023-02-21">FL</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-02-21_to_2023-02-21">33431</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Office) (Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-02-21_to_2023-02-21">(561)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-02-21_to_2023-02-21">961-1900</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of Each Class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of Each Exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on Which Registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-02-21_to_2023-02-21">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-02-21_to_2023-02-21">TXMD</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 <span style="white-space:nowrap">(&#167;230-405)</span> or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2).</span> Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Walker Employment Agreement Amendment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;21, 2023, TherapeuticsMD, Inc., a Nevada corporation (the &#8220;Company&#8221;), entered into an Amendment (the &#8220;Amendment&#8221;) to that certain Employment Agreement, dated December&#160;18, 2018, as extended effective October&#160;15, 2021 (the &#8220;Employment Agreement&#8221;), with Mr.&#160;Marlan Walker, the Company&#8217;s Chief Executive Officer. Pursuant to the terms of the Amendment, as of December&#160;30, 2022 (the &#8220;Effective Date&#8221;), Mr.&#160;Walker will receive a base salary of $428,000 per year until April&#160;15, 2023; thereafter, Mr.&#160;Walker will receive (i)&#160;a base salary of $500,000 per year and (ii)&#160;a <span style="white-space:nowrap">lump-sum</span> bonus of $20,909. Mr.&#160;Walker also received a grant of 70,000 restricted stock units that will vest on the <span style="white-space:nowrap">six-month</span> anniversary of the Effective Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amendment, in the event that Mr.&#160;Walker&#8217;s employment is terminated by the Company without Good Cause or by Mr.&#160;Walker with Good Reason (in each case as defined in the Employment Agreement), (i) Mr.&#160;Walker will continue to receive his then current base salary for 18 months following the effective date of such termination, (ii)&#160;Mr.&#160;Walker will receive an amount equal to one half times his Targeted Annual Bonus Award (as that term is defined in the Employment Agreement) for the year in which the termination occurs, (iii)&#160;Mr.&#160;Walker will receive a monthly payment equal to the monthly cost of COBRA continuation health insurance benefits for a period of twenty-four months, (iv)&#160;all unvested equity compensation of any kind held by Mr.&#160;Walker will vest as of the termination date, (v)&#160;Mr.&#160;Walker will receive a payment for accrued but unused PTO, and (vi)&#160;Mr.&#160;Walker will receive any earned but unpaid annual short-term incentive compensation for the calendar year immediately preceding the calendar year in which termination occurs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Donegan Consulting Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, on January&#160;11, 2023, TherapeuticsMD, Inc., a Nevada corporation (the &#8220;Company&#8221;), terminated that certain amended and restated employment agreement, dated November&#160;24, 2020, by and between the Company and Mr.&#160;Michael Donegan, the Company&#8217;s former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;21, 2023, the Company entered into a General Consulting and Services Agreement (the &#8220;Consulting Agreement&#8221;) with MCD Consulting and Management Services, LLC (&#8220;MCD&#8221;), the manager of which is Mr.&#160;Donegan, the Company&#8217;s Principal Financial Officer (&#8220;PFO&#8221;) and Principal Accounting Officer (&#8220;PAO&#8221;) and former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance. Pursuant to the Consulting Agreement, Mr.&#160;Donegan will provide consulting services deemed to be the functional equivalent of services normally and customarily provided by an employed chief financial officer and will continue to serve as the Company&#8217;s PFO and PAO. The Consulting Agreement will be in effect until the completion of Mr.&#160;Donegan&#8217;s services, which is anticipated to be the close of business on March&#160;31, 2023 (the &#8220;Termination Date&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Consulting Agreement, MCD received a signing fee of $100,000 and will receive an additional fee of $50,000 per month. If the term of the Consulting Agreement is extended past the Termination Date, MCD will receive an hourly fee of $205.28 per hour of services performed by Mr.&#160;Donegan. If the Consulting Agreement is not terminated by MCD prior to the Termination Date, or by the Company due to MCD&#8217;s material breach prior to the Termination Date, MCD will receive an additional <span style="white-space:nowrap">one-time</span> fee of $100,000 on the Termination Date. In addition, Mr.&#160;Donegan received a grant of 50,000 restricted stock units that will completely vest on the Termination Date, provided that the Consulting Agreement is not terminated by MCD prior to the Termination Date, or by the Company due to MCD&#8217;s material breach prior to the Termination Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Amendment and the Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment and the Consulting Agreement, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and are incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="text-decoration:underline">Exhibit Index </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d372195dex101.htm">Amendment, dated February<span style="text-decoration:underline"></span>&#160;21, 2023, to the Employment Agreement, dated as of December<span style="text-decoration:underline"></span>&#160;18, 2018, as extended effective October<span style="text-decoration:underline"></span>&#160;15, 2021, by and between TherapeuticsMD, Inc. and Marlan Walker. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d372195dex102.htm">General Consulting and Services Agreement by and between TherapeuticsMD, Inc. and MCD Consulting Management Services, LLC, dated February 21, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;27, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">THERAPEUTICSMD, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marlan Walker</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Marlan Walker</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d372195dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDMENT TO EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Second Amendment (&#147;Second Amendment&#148;) to the Employment Agreement (&#147;Agreement&#148;), effective December&nbsp;18, 2018, as
extended effective October&nbsp;15, 2021, is entered into by and between <B>TherapeuticsMD, Inc.</B> with a place of business at 6800 Broken Sound Parkway NW, 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Floor, Boca Raton, Florida 33487
(&#147;TherapeuticsMD&#148;); and <B>Marlan Walker</B> (&#147;Executive&#148;). This Second Amendment will be effective as of December&nbsp;30, 2022 (the &#147;Effective Date&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> &nbsp;&nbsp;&nbsp;&nbsp;the Agreement exists between TherapeuticsMD and Executive (collectively herein as the
&#147;Parties&#148;) relating to Executive&#146;s employment with TherapeuticsMD; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company acknowledges that as of
December&nbsp;30, 2022 Executive was appointed to be the Principle Executive Officer, which constitutes Good Reason under his employment contract with the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>Executive has agreed to waive his right to otherwise terminate for Good Reason during the Term except as defined in the Second
Amendment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHERE</B><B>AS</B><B>,</B> in accepting the role of Principle Executive Officer, Executive is taking on greater
responsibility and personal risk; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Parties have agreed to amend various terms of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of the mutual promises set forth herein and for other good and valuable consideration, the receipt and
sufficiency of which the Parties hereby acknowledge, intending to be legally bound, the Parties hereby agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;1(a) is deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employment and Term</B>2. . The Company hereby agrees to continue to employ Executive, and Executive hereby
agrees to continue to serve the Company, in accordance with the terms and conditions set forth herein, unless sooner terminated pursuant to <U>Section</U><U></U><U>&nbsp;3</U> hereof (the &#147;Term&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;1(b) is deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Duties of Executive</B>. Executive shall serve as the Company&#146;s Chief Executive Officer (the
&#147;CEO&#148;), shall diligently perform all services as may be reasonably assigned to Executive by the Company&#146;s Board of Directors (the &#147;Board&#148;), and shall exercise such power and authority as may from time to time be delegated to
Executive by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2(a) is deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Base Salary</B>.<B> </B>Effective on the Effective Date, the base salary (&#147;Base Salary&#148;) payable
to Executive shall be four hundred twenty-eight thousand dollars ($428,000) per year until April&nbsp;15, 2023 payable on a regular basis in </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
accordance with the Company&#146;s standard payroll procedures as of the end of 2022; thereafter Company will pay Executive (i)&nbsp;a Base Salary equal to five hundred thousand dollars
($500,000) per year on a regular basis in accordance with the Company&#146;s standard payroll procedures as of the end of 2022, and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">lump-sum</FONT> bonus payment of twenty thousand nine hundred nine and
fifty-nine <FONT STYLE="white-space:nowrap">one-hundredths</FONT> dollars ($20,909.59) paid no later than May&nbsp;15, 2023. Notwithstanding the foregoing, for the purposes of Section&nbsp;3(b) (&#147;Result of Termination&#148;), Executive&#146;s
salary will be five hundred thousand ($500,000) dollars.<B> </B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2(b) Annual Short-Term Incentive is hereby amended to replace &#147;forty percent (40%)&#148; with
&#147;fifty percent (50%).&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;2(f)(i) is deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Insurance Coverage.</B> During the Term, the Company shall pay for and make available to Executive all employee benefits to which other
executives of the Company are entitled to receive, subject to the eligibility requirements and other provisions of such arrangements as applicable to executives of the Company generally. Such benefits shall include, but shall not be limited to,
comprehensive health and major medical insurance, dental, vision, and short-term and long-term disability. If, during the Term, Executive the Company no longer offers comprehensive health and major medical insurance, dental, or vision insurance
requiring Executive to enroll in COBRA, Company will pay 100% of COBRA premiums. If, during the Term and during any post-separation term under Section&nbsp;3(b)(ii) or 3(b)(iv), Executive purchases short-term and long-term disability coverage at a
level equivalent to that of the benefits formerly provided by Company due to loss of coverage under Company&#146;s disability policy, Company will pay 100% of the premium for any such policy obtained by Executive for the applicable term(s). During
the Term, the Company will maintain customary director and officer insurance and, if Executive is required to continue to act as legal counsel to the Company, other insurance coverage typically provided for the benefit of <FONT
STYLE="white-space:nowrap">in-house</FONT> legal counsel, including legal liability coverage, as reasonably necessary. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Section&nbsp;2(g) is added to read as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>2023 RSU Grant. </B>Subject to Board approval, the Company will grant to Executive a 2023 equity grant in
the form of 70,000 restricted stock units pursuant to the TherapeuticsMD, Inc. 2019 Stock Incentive Plan and applicable award agreement (the &#147;2023 RSU Grant&#148;). The 2023 RSU Grant will vest on the
<FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the Effective Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To replace Section&nbsp;3(a)(vi) with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Termination by Executive With Good Reason. </B>At any time during the Term, Executive may terminate Executive&#146;s employment and the Term
for Good Reason. For purposes of this Agreement, &#147;Good Reason&#148; shall mean (A)&nbsp;the assignment to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Executive of material duties inconsistent with Executive&#146;s position as the Chief Executive Officer (including status, office, titles and reporting requirements), or any other action by the
Company that results in a material diminution in such position, excluding for this purpose (i)&nbsp;any action not taken in bad faith and that is remedied by the Company promptly after receipt of a Notice of Termination for Good Reason (as defined
below) thereof given by Executive and (ii)&nbsp;any change in status, office, titles and reporting requirements following a Change in Control of the Company in which the Company ceases to be a standalone public reporting company, provided that the
material duties of Executive following such Change in Control are not inconsistent with those of Executive immediately prior to such Change in Control; (B)&nbsp;the Company requiring Executive to be based at any office or location other than in Palm
Beach County, Florida, or within thirty-five (35)&nbsp;miles of such location, or such other location as mutually agreed to by the Company and Executive, except for travel reasonably required in the performance of Executive&#146;s responsibilities;
and (C)&nbsp;any material failure by the Company to comply with any of the provisions of this Agreement, other than a failure not occurring in bad faith and that is remedied by the Company promptly after receipt of a Notice of Termination for Good
Reason given thereof by Executive. A termination of employment by Executive for Good Reason shall be effected by Executive&#146;s giving the Board written notice (&#147;<U>Notice of Termination for Good Reason</U>&#148;) of the termination, setting
forth in reasonable detail the specific conduct of the Company that constitutes Good Reason and the specific provision(s) of this Agreement on which Executive relies, within ninety (90)&nbsp;days of the initial existence of one of the conditions
constituting Good Reason, which expressly includes Executive&#146;s appointment as Principle Executive Officer. A termination of employment by Executive for Good Reason shall be effective on the thirty-first (31st) day following the date when the
Notice of Termination for Good Reason is given to the Company; provided that such a termination of employment shall not become effective if the Company shall have substantially corrected the circumstance giving rise to the Notice of Termination for
Good Reason within thirty (30)&nbsp;days after the Company&#146;s receipt of such Notice of Termination for Good Reason. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;3(b)(ii) is deleted in its entirety and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In the event of the termination of Executive&#146;s employment and the Term pursuant to Sections 3(a)(iv) (&#147;Termination by the Company
Without Good Cause&#148;) or 3(a)(vi)&nbsp;(&#147;Termination by Executive With Good Reason&#148;) above, (a)&nbsp;Executive shall, for a period of eighteen (18)&nbsp;months following the effective date of such termination, continue to receive
Executive&#146;s then current annual Base Salary, as provided in <U>Section</U><U></U><U>&nbsp;2(a)</U>, (b) Executive shall receive an amount equal to one and one half times (1.5x) Executive&#146;s Targeted Annual Bonus Award for the calendar year
in which the termination of Executive&#146;s employment occurs, which amount shall be paid to Executive in a single lump sum on the first payroll date occurring on or after the thirtieth (30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>)
day following the effective date of the termination of Executive&#146;s employment under this Agreement, (c)&nbsp;Executive shall receive, beginning on the first payroll date occurring on or after the thirtieth (30th) day following the effective
date of the termination of Executive&#146;s employment under </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
this Agreement and for a period of twenty-four (24)&nbsp;months thereafter for a total of twenty-four (24)&nbsp;monthly payments, a monthly cash payment equal to the one (1)&nbsp;month cost of
COBRA continuation of the health insurance benefits for Executive and Executive&#146;s immediate family as applicable, as the effective date of such termination, less, the one (1)&nbsp;month cost for the same health insurance benefits for Executive
and Executive&#146;s immediate family as applicable that would have been incurred by Executive immediately prior to the effective date of such termination if Executive remained employed with the Company, (d)&nbsp;all unvested equity compensation of
any kind (including, without limitation, stock options, restricted stock, or restricted stock units) held by Executive in Executive&#146;s capacity as an employee of the Company on the effective date of the termination shall vest as of the effective
date of such termination, (e)&nbsp;Executive shall receive payment for accrued but unused PTO consistent with the Company&#146;s policies and procedures therefor in effect at the time of such termination for officers of Executive&#146;s level, and
(f)&nbsp;Executive shall receive payment for any annual short-term incentive compensation earned pursuant to Section&nbsp;2(b) hereof for the calendar year immediately preceding the calendar year in which the termination of Executive&#146;s
employment occurs which is unpaid on the effective date of Executive&#146;s termination, which shall be paid to Executive when paid to other similarly situated executives of the Company in accordance with Section&nbsp;2(b) hereof. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;3(b)(iv)(c) is hereby deleted in its entirety. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as specifically referenced herein, the Agreement shall remain unchanged and shall continue in full force
and effect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Amendment may be executed in any number of counterparts, each of which shall be enforceable against
the Parties actually executing such counterparts, and all of which shall constitute one instrument. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>TherapeuticsMD, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tommy Thompson<B> </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date: February&nbsp;21, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson, Executive Chair of the Board</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Printed Name and Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Marlan Walker</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>Marlan Walker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date: February&nbsp;21, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Marlan Walker, Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Printed Name and Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d372195dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GENERAL CONSULTING AND SERVICES AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This General Consulting and Services Agreement (this &#147;<I>Agreement</I>&#148;) is made as of the date of last signature
(&#147;<I>Effective Date</I>&#148;) by and between <B>TherapeuticsMD, Inc.</B>, a Nevada corporation maintaining offices at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431 (&#147;<I>TherapeuticsMD</I>&#148;), and <B>MCD Consulting and
Management Services, LLC</B>, a Florida limited liability company (&#147;<I>Consultant</I>&#148;). TherapeuticsMD and Consultant are sometimes referred to individually as a &#147;<I>Party</I>&#148; or collectively as the &#147;<I>Parties</I>.&#148;
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>W I T N E S S E T H </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, TherapeuticsMD is in the trade or business of the research, manufacture, promotion, and sale of pharmaceutical and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> products and other scientific materials; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Consultant&#146;s manager, Michael C. Donegan (&#147;Donegan&#148;), experienced a separation from service as an employee of
TherapeuticsMD and has been providing certain limited services; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Donegan has certain experience, knowledge, and unique
abilities that TherapeuticsMD wishes to utilize in connection with TherapeuticsMD&#146;s business and overall strategic planning; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Donegan via Consultant is willing to provide services to TherapeuticsMD, and Consultant is willing to accept such engagement
upon the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the mutual promises and covenants
contained herein, the Parties agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>CONSTRUCTION AND DEFINITIONS</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Construction</B><B><I>.</I></B><B> </B>Unless otherwise explicitly specified, this Agreement is to be
interpreted such that (a)&nbsp;words denoting the singular will include the plural and vice versa; (b)&nbsp;the terms &#147;include,&#148; &#147;including,&#148; &#147;comprise,&#148; &#147;comprises,&#148; and words of similar effect are used in
the inclusive sense of &#147;including, without limitation; (c) &#147;or&#148; is used in the inclusive sense of &#147;or&#148; (i.e., &#147;and/or&#148;) unless used in connection with the word &#147;either,&#148; &#147;unless,&#148;
&#147;alternatively,&#148; and words of similar effect; (d) &#147;any&#148; is used in the sense of &#147;any or all&#148;; (e) &#147;herein,&#148; &#147;hereof,&#148; &#147;hereunder,&#148; and words of similar effect refer to the entirety of this
Agreement; and (f) &#147;days&#148; refer to calendar days. The language of this Agreement will be construed according to its fair meaning and not strictly against either Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><I>Confidential Information (Proprietary</I></B><I> </I><B><I>Information)</I></B> will include, but
not be limited to, new product information and relating marketing plans or materials, scientific information, clinical development data, formulations, methods and processes, specifications, <FONT STYLE="white-space:nowrap">know-how</FONT> and any
other intellectual property. In addition, &#147;<I>Confidential Information</I>&#148; may include material, <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning TherapeuticsMD or its affiliates, as well as other companies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><I>Consultant Intellectual Property</I></B>&#148; means any and all patents, patent applications,
copyrights, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, trade secrets, and any other intellectual property rights owned, licensed, or controlled by Consultant as of the Effective Date. Consultant Intellectual Property will not
include any and all intellectual property rights in or derived from (a)&nbsp;Work Product or (b)&nbsp;Inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><I>Consultant Representatives</I></B>&#148; means any employees, associates, agents or subcontractors
used by Consultant to perform the Services. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B><I>Invention</I></B><B>&#148;</B><B> </B>means any discovery or invention conceived of, or made
by, Consultant or any Consultant Representative arising out of such Consultant&#146;s or Consultant Representative&#146;s participation in any Services conducted under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><I>Marks</I></B>&#148; means trademarks, trade names, service marks, logos, and symbols.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B><I>Services</I></B><B>&#148;</B> means consultation, supervisory, and advisory services as
described in Schedule A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#147;</B><B><I>TherapeuticsMD Intellectual Property</I></B><B>&#148; </B>means any and all patents, patent
applications, copyrights, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, trade secrets, and any other intellectual property rights owned, licensed, or controlled by TherapeuticsMD. TherapeuticsMD Intellectual Property will also
include any and all intellectual property rights arising from or relating to (a)&nbsp;Work Product or (b)&nbsp;Inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><I>Work Product</I></B>&#148; means any and all materials or information including documents, reports,
concepts, products, results, samples, or data produced in the course of, or as a result of, performing the Services. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>SCOPE OF SERVICES</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">TherapeuticsMD engages Consultant, and Consultant accepts such engagement, to provide certain Services to
TherapeuticsMD in connection with the project set forth in the attached <B><U>Schedule A</U></B>, which Schedule is made a part of this Agreement as if fully included herein. Any special or related service which the Parties agree is outside the
scope of the Services to be provided hereunder shall be covered under a separate written agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In performing the Services under this Agreement, Consultant shall report and be responsible to the
TherapeuticsMD employee subsequently designated by TherapeuticsMD. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consultant shall faithfully perform the Services and, upon TherapeuticsMD&#146;s request, shall provide such
additional assistance to TherapeuticsMD in such areas as Consultant is competent; provided, however, that any material change in the expected scope of Services or the Term as a result of any such request shall be memorialized in a written amendment
to this Agreement. Consultant shall also use reasonable and diligent efforts and such working time and energy as may be required for the satisfactory performance of the Services in accordance with the requests and instructions from TherapeuticsMD.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is expressly understood and agreed that the inability of Consultant to render the Services to TherapeuticsMD
by reason of absences, temporary or permanent illness, disability or incapacity, or for any other cause, shall be deemed a material breach or default hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>COMPENSATION</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, TherapeuticsMD agrees to pay to Consultant, as full and complete payment for
the performance of the Services during the project, the amount indicated in <B><U>Schedule A</U></B>. Consultant acknowledges that Consultant is not entitled to any other compensation or remuneration of any kind whatsoever unless specifically
indicated in <B><U>Schedule A</U></B>; provided, however, nothing in this Agreement is intended to impact, limit, or otherwise restrict amounts due and payable to Donegan under other agreements between Donegan and TherapeuticsMD.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The compensation provided above shall be Consultant&#146;s sole form of compensation provided by TherapeuticsMD
for the Services provided unless covered by a separate written agreement, and Consultant waives any right to royalties, additional fees or any other form of compensation whatsoever from TherapeuticsMD. As stated in Section&nbsp;3.1, nothing in this
Agreement is intended to impact, limit, or otherwise restrict amounts due and payable to Donegan under other agreements between Donegan and TherapeuticsMD. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>CONSULTANT&#146;S REPRESENTATIONS AND OBLIGATIONS</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consultant represents and warrants to TherapeuticsMD that Consultant is not now nor shall be during the term of
this Agreement a party to any other agreement or under any obligation to or restriction by any third party which would prevent Consultant from entering into this Agreement or which would adversely affect this Agreement, Consultant&#146;s performance
of the Services or any of the undertakings set forth herein in any manner. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of litigation, anticipated litigation, a dispute, or potential dispute between TherapeuticsMD and
a third party regarding or related to the subject matter of the Services provided by Consultant, Consultant agrees to provide such reasonable assistance as TherapeuticsMD may request from time to time in an effort to resolve such conflict.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Consultant receives a request or demand, by subpoena (including administrative subpoenas) or
other judicial order, related to or arising from the Services provided under this Agreement, Consultant will, in addition to invoking and preserving any applicable privilege or other protection available under any applicable Federal Law, state law
(including any state rules of civil procedure or evidence), the Federal Rules of Civil Procedure, Federal Rules of Evidence, or pertinent case law, provide immediate notice to TherapeuticsMD of the existence of the request, demand, or order and in
any case, must provide such notice within three (3)&nbsp;business days of receipt (at the latest) and provide TherapeuticsMD with a copy of the same. If Consultant receives such a request, demand or order, Consultant will not voluntarily surrender
any information without first providing TherapeuticsMD a reasonable opportunity to protect its interests including, but not limited to, by motion in an appropriate court or through a similar mechanism. TherapeuticsMD will represent Consultant in the
relevant matter or provide counsel for Consultant at TherapeuticsMD&#146;s cost, provided such representation or provision of counsel does not create a conflict of interest that would otherwise preclude such representation of Consultant.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the term of this Agreement, and for a period of five (5)&nbsp;years thereafter unless otherwise
obligated under this Agreement, Consultant will keep all records relating to the performance of the Services hereunder. Consultant will at any time during the term of this Agreement, at TherapeuticsMD&#146;s request, and in any event upon the
termination of this Agreement (regardless of the reason), (a) deliver to TherapeuticsMD copies of any and all records, documents, memoranda, books, papers, letters, notes, notebooks, reports, and any and all other data and information (in whatever
form), together with any copies or abstracts thereof, resulting from the performance of the Services hereunder or as may have been provided by TherapeuticsMD to Consultant; or (b)&nbsp;destroy such records (and if requested, provide certification to
TherapeuticsMD that such records have been destroyed). Notwithstanding the foregoing, during the term of this Agreement and for the five (5)&nbsp;year period thereafter, in the event TherapeuticsMD notifies Consultant in writing that any information
in Consultant&#146;s possession related to any Services is subject to a &#147;litigation hold,&#148; Consultant shall, in accordance with any TherapeuticsMD prescribed directive, take all necessary affirmative actions to ensure that such information
is preserved and not destroyed until such time as Consultant is otherwise notified by TherapeuticsMD in writing. Any additional reasonable costs incurred by Consultant in furtherance of a litigation hold will be paid by TherapeuticsMD provided that
Consultant has received written approval to incur such costs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consultant represents and warrants that it shall perform all Services under this Agreement in a diligent,
workmanlike, and professional manner. Consultant warrants that the provision of any goods and services hereunder shall be in accordance with all applicable federal, state and local laws including any law, order or regulatory provision concerning
equal employment opportunities by federal contractors and including, without limitation, those related to the advertising and promotion of prescription or device products. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consultant represents and warrants that all deliverables and/or Work Product produced under this Agreement
(a)&nbsp;will perform in accordance with all documentation provided by Consultant and (b)&nbsp;along with all Consultant Intellectual Property, shall be of original development or licensable by Consultant, as the case may be. Consultant represents
and warrants that all deliverables, Work Product and Consultant Intellectual Property licensed or owned by Consultant and used in the performance of any statement of work shall not infringe or violate any patent, copyright, trade secret, trademark,
or other third party intellectual property right. Consultant represents and warrants that the deliverables and/or Work Product to be provided under any Statement of Work is/are not the subject of a lien, a security interest, claim, cause of action
or otherwise hypothecated to a third party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Consultant&#146;s status as an independent contractor, Consultant acknowledges and specifically
agrees to comply at all times with applicable federal and state securities laws and regulations when trading in any securities of TherapeuticsMD or when trading in any securities of any other company while possessing material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information concerning that company which was obtained during the course of performing the Services for TherapeuticsMD. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>CONFIDENTIALITY</U></B><B><U></U></B><B><U>&nbsp;&amp; PRIVILEGE</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any provision in this Agreement to the contrary, Consultant (together with Consultant&#146;s
Representatives) shall hold confidential and shall not, directly or indirectly, disclose, publish, or use for the benefit of Consultant or any third party, except solely in carrying out Consultant&#146;s duties for TherapeuticsMD hereunder, any
Confidential Information of TherapeuticsMD, without first having obtained TherapeuticsMD&#146;s written consent to such disclosure or use. Consultant acknowledges, confirms, and agrees that Consultant is aware that any trading of securities by a
person in possession of any such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information is subject to regulation and requirements of federal and state securities laws. This restriction shall not apply if the information shall have
become public knowledge without fault on the part of Consultant (or any of Consultant Representatives). Notwithstanding any provision in this Agreement to the contrary, this obligation shall survive the termination of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During the Term of this Agreement: (i)&nbsp;Consultant will not encourage or solicit any employee or consultant
of TherapeuticsMD to leave TherapeuticsMD for any reason, (ii)&nbsp;Consultant will not engage in any activity that is in any way competitive with the business or demonstrably anticipated business of TherapeuticsMD, and (iii)&nbsp;Consultant will
not assist any other person or organization in competing or in preparing to compete with any business or demonstrably anticipated business of TherapeuticsMD. Consultant acknowledges that the foregoing obligations are reasonable and that Consultant
will not be precluded from making a living by obligation not to compete with TherapeuticsMD during the period described above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consultant and TherapeuticsMD acknowledge that in the event of a breach of this Section&nbsp;5 of the
Agreement, TherapeuticsMD (i)&nbsp;will be irreparably harmed; (ii)&nbsp;will be entitled to injunctive relief; and (iii)&nbsp;without the requirement for posting bond or proving actual, irreparable damages that may not be fully remedied by monetary
damages. Consultant and TherapeuticsMD therefore agree that TherapeuticsMD shall be entitled to seek injunctive relief against any such breach in any court of competent jurisdiction and Consultant shall be responsible for all costs associated with
such injunctive relief, provided that TherapeuticsMD prevails in the action. In the event that TherapeuticsMD is successful TherapeuticsMD&#146;s rights under this <U>Section</U><U></U><U>&nbsp;5</U> shall not in any way be construed to limit or
restrict its rights to seek other damages or relief available under this Agreement or applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Defend Trade Secrets Act</U></B>. Each Party agrees that it is hereby notified in accordance with the
Defend Trade Secrets Act of 2016 that such Party will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a)&nbsp;is made (i)&nbsp;in confidence to a federal, state, or
local government official, either directly or indirectly, or to an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
attorney; and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (b)&nbsp;is made in a complaint or other document that is filed under seal in a
lawsuit or other proceeding. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Whistleblower Provision</U></B>. Nothing in this Agreement shall be construed to prevent disclosure of
Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that such disclosure does not exceed the extent of
disclosure required by such law, regulation or order. Each Party agrees to provide prompt written notice of any such order to the other Party to the extent permitted by such law, regulation or order. Each Party understands that this Agreement does
not prohibit or restrict such Party from communicating with a government agency, as provided for, protected under, or warranted by applicable law, without notice to the other Party, or limit the Party&#146;s right to receive an award for information
provided to a government agency. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>TERM OF AGREEMENT</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall become effective as of the Effective Date until the period indicated in <B><U>Schedule
A</U></B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be terminated by Consultant without cause on ninety (90)&nbsp;days prior written notice and
by TherapeuticsMD immediately upon written notice. In the event TherapeuticsMD terminates Consultant for convenience after the Effective Date, provided Consultant has substantially complied with Consultant&#146;s obligations hereunder, Consultant
shall be paid the additional fee due and payable on March&nbsp;31, 2023 (per Schedule A, Section&nbsp;3b), and the restricted stock units shall vest on March&nbsp;31, 2023 (per Schedule A, Section&nbsp;3c). For amounts due and payable under Schedule
A, Section&nbsp;3a, provided Consultant has not breached this Agreement, Consultant shall be entitled to payment hereunder with respect to actual charges incurred up to the effective date of the termination, provided that Consultant stops all work
to the extent specified in the notice, completes performance of such work that has not been terminated, and invoices TherapeuticsMD for amounts owed within thirty (30)&nbsp;days of termination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If either TherapeuticsMD or Consultant breaches any representation made herein or fails to abide by any of the
terms of this Agreement, the other Party shall have the right to terminate this Agreement upon thirty (30)&nbsp;days prior written notice to the defaulting Party specifying the default; <U>provided</U>, <U>however</U>, if said defaulting Party cures
the default within the said thirty (30)&nbsp;day period, this Agreement shall continue in full force and effect as if no default had occurred. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of this Agreement for any cause or for no cause, or at any earlier time upon the demand of
TherapeuticsMD, Consultant shall, without cost to TherapeuticsMD, (a)&nbsp;deliver to TherapeuticsMD in an orderly and expeditious manner all data, records, documentation, and other property belonging to TherapeuticsMD then in the possession of
Consultant, including, but not limited to, the Work Product and all copies, extracts, summaries, and portions thereof, on whatever media rendered; (b)&nbsp;purge from its computer systems any Work Product and all copies, extracts, summaries, and
portions thereof; and (c)&nbsp;upon request of TherapeuticsMD, certify in writing that it has complied with these requirements. Notwithstanding anything to the contrary contained in this Agreement, if Consultant breaches any term or condition of
this Agreement, TherapeuticsMD may, at its option, exercise any one or more of the following remedies: (i)&nbsp;terminate this Agreement, effective immediately upon written notice to Consultant; (ii)&nbsp;withhold any further payments otherwise due
to Consultant hereunder; or (iii)&nbsp;exercise any other rights and remedies available at law or in equity. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>INDEPENDENT CONTRACTOR</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consultant is retained by TherapeuticsMD only for the purposes and to the extent set forth in this Agreement, and Consultant&#146;s relation to TherapeuticsMD
shall, during the period or periods of its rendering of the Services, be that of an independent contractor. Consultant shall be free to dispose of such portion of its time, energy and skill as Consultant
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sees fit to accomplish the Services. Consultant shall not be considered under the provisions of this Agreement or otherwise as having any employee status or as being entitled to participate in
any benefit plans or arrangements provided by TherapeuticsMD to its regular employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement is intended to, or should be construed
to, create a partnership, agency, joint venture or employment relationship between TherapeuticsMD and any of Consultant&#146;s employees or agents. Consultant and Consultant&#146;s employees, if any, will not be entitled to any of the benefits that
TherapeuticsMD may make available to its employees, including, but not limited to, group health or life insurance, profit-sharing or retirement benefits. Because Consultant is an independent contractor, TherapeuticsMD will not withhold or make
payments for social security, make unemployment insurance or disability insurance contributions, or obtain workers&#146; compensation insurance on behalf of Consultant. Consultant is solely responsible for, and will file, on a timely basis, all tax
returns and payments required to be filed with, or made to, any federal, state or local tax authority with respect to the performance of Services and receipt of fees under this Agreement. Consultant is solely responsible for, and must maintain
adequate records of, expenses incurred in the course of performing Services under this Agreement. No part of Consultant&#146;s compensation will be subject to withholding by TherapeuticsMD for the payment of any social security, federal, state or
any other employee payroll taxes. TherapeuticsMD will regularly report amounts paid to Consultant by filing Form <FONT STYLE="white-space:nowrap">1099-NEC</FONT> with the Internal Revenue Service as required by law. If, notwithstanding the
foregoing, Consultant is reclassified as an employee of TherapeuticsMD, or any affiliate of TherapeuticsMD, by the U.S. Internal Revenue Service, the U.S. Department of Labor, or any other federal or state or foreign agency as the result of any
administrative or judicial proceeding, Consultant agrees that Consultant will not, as the result of such reclassification, be entitled to or eligible for, on either a prospective or retrospective basis, any employee benefits under any plans or
programs established or maintained by TherapeuticsMD. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>INDEMNIFICATION</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>By TherapeuticsMD.</U></I></B> TherapeuticsMD shall defend, indemnify and hold Consultant harmless
from, against, for and in respect of any and all damages, losses, costs and expenses (including, without limitation, reasonable attorneys&#146; fees, and any special, incidental, exemplary, punitive, consequential (which, for purposes of this
Agreement, shall include, without limitation, any lost profits or sales, or indirect damages) damages arising out of any third party suit, action or proceeding for bodily injury, death or property damage related to Consultant&#146;s Services
hereunder, if and to the extent such injury, death or damage is caused by any product, service, overt act, or omission of TherapeuticsMD; provided, however, that TherapeuticsMD&#146;s obligations hereunder shall not apply in the event that any such
injury, death or damage was caused in any manner by Consultant or any of its directors, officers, employees, agents, or any Consultant Representative. The term &#147;<I>cause</I>&#148; shall be meant to include, without limitation, Consultant&#146;s
failure to follow instructions or protocols issued by TherapeuticsMD, Consultant&#146;s (or any Consultant Representative&#146;s) failure to follow any applicable governmental or institutional requirements, or any acts of negligence or willful
misconduct by Consultant or any Consultant Representative. Further, TherapeuticsMD shall defend, indemnify and hold Consultant harmless from, against, for and in respect of any and all claims, damages, losses, costs and expenses (including, without
limitation, reasonable attorneys&#146; fees) arising out of any third party demand, claim, suit, action or proceeding for any alleged violations of any laws or regulations governing financial reporting, alleged violations or breaches of any
corporate duties, or other claims for economic losses related to Consultant&#146;s Services hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>Claims.</U></I></B> Promptly upon receiving notice of any claim or action for which a Party wishes to
seek indemnification hereunder, such Party shall promptly notify the other in writing of the assertion of any such claim, suit, action or proceeding. Failure to provide such notice which substantially prejudices the indemnifying Party&#146;s ability
to defend such claim or action may invalidate any obligation of indemnification. Notwithstanding the foregoing, any Party seeking to be indemnified shall nevertheless be entitled to retain separate counsel at its own costs to participate in such
matter; however, the indemnifying Party shall have sole case management authority; provided, however, Consultant may not compromise or settle any matter without TherapeuticsMD&#146;s prior written consent, not to be unreasonably withheld. Any Party
seeking indemnification shall fully cooperate with the indemnifying Party. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>D&amp;O Insurance</U></I></B>. TherapeuticsMD shall maintain in full force and effect all D&amp;O
insurance through and including the Term of this Agreement, which insurance shall extend to Donegan and the provision of Services contemplated hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>OWNERSHIP OF DATA, PATENTS, INVENTIONS, AND </U><U>INTELLECTUAL PROPERTY</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>TherapeuticsMD Intellectual Property and Work Product.</U></I></B> Consultant acknowledges that
TherapeuticsMD Intellectual Property is the exclusive property of TherapeuticsMD or its licensors. Consultant further acknowledges that the Work Product and any and all other intellectual property rights developed, derived from, or otherwise
generated by Consultant in performing Services hereunder, will be owned by and belong exclusively to TherapeuticsMD. As evidenced by the Assignment in the form attached as <B><U>Exhibit A</U></B>, Consultant hereby assigns to TherapeuticsMD the
ownership of all rights, titles, and interests in all patents, trade secrets, or other intellectual property rights in, relating to, or arising from Work Product, Services, or Inventions. Ownership of copyrights is addressed in Section&nbsp;9.3.
Consultant further agrees to give TherapeuticsMD and its designees or assignees all assistance reasonably required to perfect such rights, titles, and interests. Consultant will not attack, dispute, or challenge TherapeuticsMD&#146;s right, title,
and interest in and to TherapeuticsMD&#146;s Intellectual Property or assist others in so doing. These obligations will survive and continue beyond the termination of Consultant&#146;s engagement with TherapeuticsMD under this Agreement and will be
binding upon Consultant&#146;s assigns, executives, administrators, and other legal representatives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>TherapeuticsMD Trademarks</U></I></B><B><I>. </I></B>Consultant will not use TherapeuticsMD&#146;s
Marks without prior written authorization from TherapeuticsMD. The Marks are, and will remain, TherapeuticsMD&#146;s sole and exclusive property, and Consultant has not acquired, and will not acquire (by operation of law, this Agreement, or
otherwise), any right, title, or interest in any of TherapeuticsMD&#146;s Marks other than as explicitly provided in writing by TherapeuticsMD. Consultant recognizes the value of the goodwill associated with TherapeuticsMD&#146;s Marks and
acknowledges that all rights therein belong exclusively to TherapeuticsMD. Any and all goodwill or rights that arise under trademark and copyright law, and all other intellectual property rights that arise in favor of TherapeuticsMD&#146;s Marks as
a result of this Agreement or otherwise, will inure to the sole and exclusive benefit of TherapeuticsMD. Consultant will not attack, dispute, or challenge TherapeuticsMD&#146;s right, title, and interest in and to TherapeuticsMD&#146;s Marks or
assist others in so doing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>Copyrights and Publications.</U></I></B> Consultant is not permitted to publish, present, display,
otherwise disclose, or submit for publication, presentation, display, or other disclosure, Work Product without prior written permission from TherapeuticsMD. TherapeuticsMD will consider any request for publication in good faith. Except as provided
in this Section&nbsp;9.3, to the extent any Work Product contains copyrightable material that can be &#147;work made for hire&#148; as the term is defined under 17 U.S.C. &#167;101, such material will be deemed &#147;work made for hire&#148; and
TherapeuticsMD will be considered the author. If such material is not deemed &#147;work made for hire,&#148; Consultant hereby assigns all copyrights in such material to TherapeuticsMD, as evidenced by the Assignment in the form attached hereto as
<B><U>Exhibit A</U></B>. If TherapeuticsMD gives permission for the publication of material based on or including Work Product, TherapeuticsMD will provide an automatic <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license(s) to such
author(s) of the material, for rights in the copyright in such material in the form and in the venue approved by TherapeuticsMD for such publication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>Inventions.</U></I></B> Consultant will promptly disclose to TherapeuticsMD any Inventions or
potential Inventions, whether or not protectable as a trade secret, patent, or otherwise, made by Consultant or any Consultant Representative. Consultant will ensure that all Consultant Representatives involved in the Services are obligated to
assign to Consultant or TherapeuticsMD all right, title, and interest each may have in any such Invention. Consultant will ensure that all Consultant Representatives </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
involved in the Services are obligated, if so requested by TherapeuticsMD, to assist in the preparation, filing, perfection, prosecution, defense, and enforcement of any patent associated with
the Invention. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><U>Consultant Intellectual Property.</U></I></B> Consultant Intellectual Property will not be included in
any Work Product unless and until Consultant identifies in writing to TherapeuticsMD the Consultant Intellectual Property proposed to be included in the Work Product, and obtains the prior written consent of TherapeuticsMD. Any Work Product that
includes Consultant Intellectual Property in violation of this Section&nbsp;9.5 is hereby automatically and perpetually licensed to TherapeuticsMD, its Affiliates, or their designees, in connection with such Work Product and any products, services,
materials, or information related thereto or arising therefrom, at no charge. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>NOTICES</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice required or permitted to be given hereunder shall be in writing and shall be (i)&nbsp;delivered personally by hand, (ii)&nbsp;sent by registered or
certified mail, or (iii)&nbsp;sent by a recognized qualified overnight delivery service (e.g., Federal Express). All such notices shall be sent postage prepaid to the addresses of each Party set forth below or to such other address or addresses as
shall be designated in writing in the same manner: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To TherapeuticsMD:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TherapeuticsMD, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Legal Dept.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">951 Yamato Road, Suite 220</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boca Raton, Florida 33431</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fax: (561) <FONT STYLE="white-space:nowrap">431-3389</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Consultant:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MCD Consulting and</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Management Services,
LLC</B></P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>DEBARMENT AND EXCLUSION CERTIFICATION</U></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consultant hereby certifies to TherapeuticsMD that Consultant is not and has not been, and that Consultant has not used, and will not use, the services of any
person (inclusive of Consultant Representatives), excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, and has not used, and will not use, the
services of any person listed on the HHS/OIG List of Excluded Individuals/Entities (<U>http://www.oig.hhs.gov</U>), the GSA&#146;s List of Parties Excluded from Federal Programs (<U>http://www.epls.gov</U>), or the FDA Debarment List
(<U>http://www.fda.gov/ora/compliance_ref/debar/default.htm</U>) in connection with any of the Services performed under this Agreement. Consultant further certifies that Consultant, and any other person or entity used by Consultant in performing any
of the Services under this Agreement, has not been convicted of a criminal offense that falls within the ambit of 42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7(a).</FONT> Consultant agrees to notify TherapeuticsMD promptly in the
event Consultant, or any person used by Consultant in connection with this Agreement, ever becomes excluded, debarred, suspended, or otherwise ineligible to participate in Federal health care programs or in Federal procurement or nonprocurement
programs. This certification applies to Consultant and in respect of officers, agent and employees of Consultant, as well as third parties with whom Consultant may subcontract. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>MISCELLANEOUS PROVISIONS</U></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement is personal in nature, and Consultant shall not, without the prior written consent of
TherapeuticsMD, assign or transfer this Agreement or any rights or obligations hereunder. TherapeuticsMD may assign or transfer this Agreement to a successor or affiliated organization, provided that in the case of any such assignment or transfer,
the assignee or transferee shall be bound by the terms and obligations provided in this Agreement. If Consultant desires to engage any employees, associates, or subcontractors in performing the Services, Consultant will ensure such persons to enter
into a written agreement, containing terms as least as restrictive as those contained herein and assigning inventions to Consultant or TherapeuticsMD as set forth herein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The captions or headings in this Agreement are for convenience only and shall not be considered a part of or
affect the construction or interpretation of any provision of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be executed simultaneously in one or more counterparts, but all such counterparts taken
together will constitute one and the same Agreement. The exchange of copies of this Agreement and of signature pages by facsimile transmission or .pdf delivered via email will constitute effective execution and delivery of this Agreement as to the
Parties and may be used in lieu of the original Agreement for all purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be governed by the laws of the State of Florida without regard for conflicts of law
principles; and Florida shall be the sole and exclusive forum for the resolution of all disputes arising under or relating to this Agreement. In the event of a dispute in respect of this Agreement, including the meaning or construction hereof, such
dispute shall be referred to a single arbitrator, mutually acceptable to the Parties, or, if no single arbitrator can be agreed upon, an arbitrator or arbitrators shall be selected in accordance with the rules of the American Arbitration Association
(&#147;AAA&#148;) and such dispute shall be settled by arbitration in accordance with the then prevailing commercial rules of the AAA. In any action or proceeding to enforce rights under this Agreement, the prevailing Party will be entitled to
recover costs and attorney&#146;s fees. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The invalidity or unenforceability of any term, provision, clause, or any portion thereof, of this Agreement
shall in no way impair or affect the validity or enforceability of any other provision of this Agreement, which remains in full force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No failure or delay by a Party to insist upon the strict performance of any term or condition under this
Agreement or to exercise any right or remedy available under this Agreement at law or in equity, and no course of dealing between the Parties, shall imply or otherwise constitute a waiver of such right or remedy, and no single or partial exercise of
any right or remedy by any Party will preclude any other or further exercise thereof. Any and all waivers must be in writing and signed by the party who is waiving their rights. All rights and remedies provided in this Agreement are cumulative and
not alternative and are in addition to all other available remedies at law or in equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should any legal action be commenced in connection with this Agreement, the prevailing Party in such action
shall be entitled to recover, in addition to court costs, such amount as the court may adjudge as reasonable attorneys&#146; fees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement constitutes the entire agreement between the Parties relating to the subject matter hereof. This
Agreement supersedes all prior understandings, negotiations and discussions, written or oral, of the Parties relating to the transactions contemplated by this Agreement. Any waiver, alteration or modification of any of the provisions in this
Agreement or any cancellation or replacement of this Agreement shall not be valid unless in writing and signed by the Parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All provisions of this Agreement and any statement of work which may reasonably be interpreted or construed as
surviving termination will survive, including without limitation, Sections 3 (Compensation), 5 (Confidentiality), 8 (Indemnification), 9 (Ownership of Data, Patents, Inventions, and Intellectual Property), and 12 (Miscellaneous Provisions).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature page follows </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties hereto have caused this Agreement to be executed by
their duly authorized officers as of the Effective Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TherapeuticsMD, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>MCD Consulting and Management Services, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marlan Walker</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Donegan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Marlan Walker</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2/21/2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2/21/2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DETAILED PROJECT/SERVICES SPECIFICATIONS </U></B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>SPECIFICATION OF SERVICES TO BE RENDERED</U>: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consultant shall provide to TherapeuticsMD consulting services relating to Consultant&#146;s expertise in accounting. Specific projects include serving as the
Company&#146;s principle financial and accounting officers, completing 2022 audit, and completing the Form <FONT STYLE="white-space:nowrap">10-K</FONT> filing, financial reporting wind down and such other projects as shall be assigned from time to
time as mutually agreed upon by the Parties (the &#147;Services&#148;). Such Services are deemed to be the functional equivalent of services normally and customarily provided by an employed chief financial officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties expressly consent to execution of the Form <FONT STYLE="white-space:nowrap">10-K</FONT> by Donegan, in his own name, as acting CFO. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>TERM</U>: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall be in effect from the Effective Date and shall remain in effect until the completion of the Services, which is anticipated to be the close
of business on March&nbsp;31, 2023. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>FEE AND METHOD OF PAYMENT</U>: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Monthly Fee </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Consultant will be paid a fee for Services rendered in accordance with the terms of this Agreement of fifty thousand dollars per month
($50,000/month) to be paid as a single lump sum on the last day of each calendar month following the Effective Date. If the Term is extended after March&nbsp;31, 2023 by mutual agreement between Consultant and TherapeuticsMD, Consultant will be paid
an hourly fee of two hundred five dollars and forty-eight cents ($205.48/hour). Consultant shall submit invoices to TherapeuticsMD on a monthly basis which shall contain a detailed itemization of the Services performed, including date, a full
description of the services provided, to whom the service was provided and the number of hours worked for each date of service. Such invoices shall be submitted to TherapeuticsMD at the address set forth in this Agreement, to the attention of
&#147;TherapeuticsMD Accounts Payable Department.&#148; TherapeuticsMD shall pay each such invoice within thirty (30)&nbsp;days of TherapeuticsMD&#146;s receipt and approval of same. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other Fee </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Consultant will be paid an additional fee of two hundred thousand dollars ($200,000) at the following milestones: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one hundred thousand dollars ($100,000) upon the execution of this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one hundred thousand dollars ($100,000) on March&nbsp;31, 2023, if this Agreement is not terminated by Consultant
prior to March&nbsp;31, 2023, or not terminated by TherapeuticsMD prior to March&nbsp;31, 2023, due to Consultant&#146;s material breach or intentionally wrongful acts. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Equity </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subject to approval by the Board of Directors of TherapeuticsMD, Consultant will receive a grant of fifty thousand (50,000) restricted stock
units that will completely vest on March&nbsp;31, 2023, provided this Agreement is not terminated by Consultant prior to March&nbsp;31, 2023, or not terminated by TherapeuticsMD prior to March&nbsp;31, 2023, due to Consultant&#146;s material breach
or Consultant&#146;s intentionally wrongful acts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consultant shall provide bank payment information to TherapeuticsMD with submission of first invoice.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For good and
valuable consideration, receipt of which is hereby acknowledged by<B> MCD Consulting and Management Services, LLC</B>, a Florida Limited Liability Company (&#147;<B>Consultant</B>&#148; or<B> &#147;ASSIGNOR</B>&#148;), Assignor has assigned, and by
this Assignment does hereby assign to <B>THERAPEUTICSMD, INC.,</B> a Nevada corporation maintaining its offices at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431 USA (&#147;<B>TherapeuticsMD</B>&#148; or &#147;<B>ASSIGNEE</B>&#148;), the
ownership of all rights, titles, and interests in all copyrights, trade secret, or other intellectual property protection and conceived of or made by or on behalf of Assignor or Assignor Representatives and arising out of such Assignor&#146;s
participation in any of the services to be performed by Assignor as set forth under the Consulting Agreement to which this assignment is attached (&#147;<B>Agreement</B>&#148;) to which this Assignment is an Exhibit, as set forth in the Agreement,
including the project agreements and schedules or exhibits thereto, including applicable Protocol(s) or Statement(s) of Work, under the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Under the Agreement to which this Assignment is an Exhibit, Assignor may obtain certain ownership interests and intellectual property,
including patents, patent applications, copyrights, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, trade secrets, and other intellectual property rights in connection with or in any way related to the Services provided under the
Agreement (&#147;Intellectual Property&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;Assignor hereby irrevocably assigns and transfers to Assignee,
Assignor&#146;s entire right, title, and interest in and to the Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Assignor agrees that,
upon request and without further compensation, Assignor and Assignor&#146;s legal representatives and assigns will do all lawful acts, including the execution of papers and the giving of truthful testimony, that may be necessary or reasonably
requested by Assignee for obtaining, sustaining, maintaining, renewing, or enforcing the Intellectual Property, and for perfecting, recording, or maintaining the title, and Assignee&#146;s successors and assigns, in and to the Intellectual Property.
In the event that Assignee is unable after reasonable attempt to secure Assignor&#146;s signature to any document in connection with the foregoing, Assignor, hereby constitutes and appoints Assignee as Assignor&#146;s true and lawful attorney in
fact, with full power of substitution in Assignor&#146;s name and stead, to take any and all steps, including proceedings at law, in equity or otherwise, to execute, acknowledge, and deliver any and all instruments and assurances necessary or
expedient in order to vest or perfect the aforesaid rights and causes of action more effectively in Assignee or to protect the same or to enforce any claim or right of any kind with respect thereto. Assignor hereby declares that the foregoing power
is coupled with an interest and as such is irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. &nbsp;&nbsp;&nbsp;&nbsp;To the extent any of the rights, title, and interest
in and to the Intellectual Property cannot be assigned as contemplated by this Assignment, Assignor hereby grants to Assignee an exclusive, royalty-free, transferable, irrevocable, worldwide license (with rights to sublicense through multiple tiers
of sublicensees) to use, make, have made, sell, import, reproduce, modify, distribute, display, and perform the Intellectual Property. To the extent any of the rights, title, and interest in and to the Intellectual Property can neither be assigned
nor licensed as contemplated by this Assignment, Assignor hereby irrevocably waives and agrees never to assert such <FONT STYLE="white-space:nowrap">non-assignable</FONT> and <FONT STYLE="white-space:nowrap">non-licensable</FONT> rights, title, and
interest against Assignee or any of Assignee&#146;s successors in interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Signature page follows </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties hereto have caused this Assignment to be executed by
their duly authorized officers as of the date last written below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Assignee: TherapeuticsMD, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Assignor: MCD Consulting and Management Services, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>txmd-20230221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/28/2023 2:10:25 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:txmd="http://www.therapeuticsmd.com/20230221"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.therapeuticsmd.com/20230221"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txmd-20230221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txmd-20230221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>txmd-20230221_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/28/2023 2:10:25 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>txmd-20230221_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/28/2023 2:10:25 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="txmd-20230221.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140124590586816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 21,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d372195d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="txmd-20230221.xsd" xlink:type="simple"/>
    <context id="duration_2023-02-21_to_2023-02-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-02-21_to_2023-02-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-02-21_to_2023-02-21"
      id="Hidden_dei_EntityCentralIndexKey">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-02-21_to_2023-02-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-02-21_to_2023-02-21">2023-02-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-02-21_to_2023-02-21">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-02-21_to_2023-02-21">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-02-21_to_2023-02-21">001-00100</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-02-21_to_2023-02-21">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-02-21_to_2023-02-21">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-02-21_to_2023-02-21">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-02-21_to_2023-02-21">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-02-21_to_2023-02-21">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-02-21_to_2023-02-21">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-02-21_to_2023-02-21">(561)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-02-21_to_2023-02-21">961-1900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-02-21_to_2023-02-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-02-21_to_2023-02-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-02-21_to_2023-02-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-02-21_to_2023-02-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-02-21_to_2023-02-21">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-02-21_to_2023-02-21">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-02-21_to_2023-02-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-02-21_to_2023-02-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &"#6U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !@@UM6<?A/$NT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)TW!A=#-1?&D(+B@> O)[&ZP^4,RTN[;V];=+J(/X#$SOWSS
M#4QGDC0QXW.."3,Y+#>C[T.1)FW9D2A)@&*.Z'6IIT28FON8O:;IF0^0M/G0
M!P3!^2UX)&TU:9B!55J)3'762)-14\QGO#4K/GWF?H%9 ]BCQT %FKH!IN:)
MZ33V'5P!,XPP^_)=0+L2E^J?V*4#[)P<BUM3PS#40[ODIAT:>'MZ?%G6K5PH
MI(/!Z5=QDDX)M^PR^;6]N]\],"6X:"LN*K'9B4:*C>3\?7;]X7<5]M&ZO?O'
MQA=!U<&ONU!?4$L#!!0    ( &"#6U:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M8(-;5C$(2N9<!   +A$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF&MSXC84AO^*QNUTVIDD6.:22X$90C;;S"99&NAN+],/PCZ )K;E2G)(_GV/
M;&+3K3DF,P3+EEX_TCEZ)3'<*OUL-@"6O29Q:D;>QMKLJM,QX0828<Y4!BD^
M62F="(M%O>Z83(.(BD9)W E\?]!)A$R]\;"X-]/CH<IM+%.8:6;R)!'Z[1IB
MM1UYW'N_\237&^MN=,;#3*QA#O:W;*:QU*E4(IE :J1*F8;5R)OPJ^N@[QH4
M-;Y(V)J]:^:ZLE3JV17NHI'G.R*((;1.0N#7"TPACIT2<ORS$_6J=[J&^]?O
MZK=%Y[$S2V%@JN*O,K*;D7?AL0A6(H_MD]K^ KL.%8"ABDWQGVW+NCW?8V%N
MK$IVC9$@D6GY+5YW ['?@!]H$.P:! 5W^:*"\D98,1YJM67:U48U=U%TM6B-
M<#)U49E;C4\EMK/C&Q7F.,B6B31B'U(K[1N[2\MHXZ@-.Q9?XJIVPIW@=2D8
M'!"\A>49"_@)"_R@^]_F'62K (,*,"CTN@?TINH%-/MKLC168PC_;B(J%7K-
M"BZOKTPF0AAYF+@&] MXXQ^^XP/_9X*O6_%U*?7Q!$<O*D;P-A;K)CJZ_4K$
M!@B.7L71(W5VL9LBB18QQC""5_8)WIJ(:"7?_07]\QX5OGZ%U2?%JOQ:O&70
MQ$(WOSC]1$ ,*HC!<1 ST%*Y/(\8SI9&'EJIRNZV]#ZOT,Z/"=L3K*5+<&1\
M%$DC&*VSV( 6&>16AN;AY@3C'YX1>!<5WL4Q>*BF=*9TX0EL;G'LV%3EF&J8
M<2IJY*6%'[\0=)<5W>4Q=+<R!O:8)TO032"TAN_S4_SX/L'#_=I-_6.(%N*5
MW468<7(EPW+0#O.U2%Z<GV*J=?O=/D6XY_?\&,))%*$7FI/W"W:/]=CGM#&4
M+9*7?<[^$+A@*/:D1$1AUJ[/2=.F,1=;U8A)2\YSB6D;!&2D:]OGM&]_"SAU
M):790FV;5TU:[EJ%@CWA$*847;T8\*-6@XJNG+*(-]/J1:9A<YAIS=M["JU>
M$#AMZ=^BS92QN&#]*;.#5M*BV.WVNIQBJ]<)3MM[$<0)[FX/H] "/_8'_"<*
MI5X7.&WH]Y@0,9MM5$IY6XO(Y8"?\DO:V^JE@-.6_55+:R'%H4F2/-WYFFFD
MHH7:MCR\]G].F_=<Q3*45J9K]H )KJ6(&WEHE3:>H+;_@/;JF89B> !G6+GK
MP<TA;E\_KU;-\6O1:R6K;3^@/?I_9'?&Y$C6"DC+M@+N;?-;W!G"7+OIQX,E
M6T@;-TZ_%A'7PV*#HL+G$Y8)S5Y$G /[WC_#-9YEV%.S$9HDKE> @+;LA1:1
MR[SY6[)4C7G7)O#[PPU%4KM]0#MS-78?7L.-2-=P<!/9(O0XF=],?J68:IL/
MCK+Y#PGHM1NECZA@-RX',Y$VGDI:! ^F6F?O].M^27@0[HV&Q;!"(?_L''5U
M>3@O"U9EQ8%XJ2P>KXO+#0B<!JX"/E\I9=\+[HQ=_40R_A=02P,$%     @
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M8(-;5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !@@UM6<?A/$NT    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !@@UM6F5R<(Q &
M  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( &"#6U8Q"$KF7 0  "X1   8              " @0P(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !@@UM6GZ ;\+$"
M  #B#   #0              @ &>#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( &"#6U:7BKL<P    !,"   +              "  7H/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( &"#6U8<.&7J/P$  #P"   /              "
M 6,0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !@@UM6)!Z;HJT   #X
M 0  &@              @ '/$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !@@UM699!YDAD!  #/ P  $P              @ &T
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d372195d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d372195d8k.htm">d372195d8k.htm</File>
    <File>d372195dex101.htm</File>
    <File>d372195dex102.htm</File>
    <File>txmd-20230221.xsd</File>
    <File>txmd-20230221_lab.xml</File>
    <File>txmd-20230221_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d372195d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d372195d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20230221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20230221_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20230221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "txmd",
   "nsuri": "http://www.therapeuticsmd.com/20230221",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d372195d8k.htm",
      "contextRef": "duration_2023-02-21_to_2023-02-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d372195d8k.htm",
      "contextRef": "duration_2023-02-21_to_2023-02-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.therapeuticsmd.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-050813-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-050813-xbrl.zip
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M;<##A!RN>U$;&0G5QJ;J:/E(9P?'@:OB::!8O:L2K;!:.^,F+B9.'4<KFQ6
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M_MD>TQR<!>@;^J%=C,2D&@./93#Z#UIAW]/Q!D9HF3<:8;@@& 1,HWDY7(1
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M>(#;/QRJWF7PG!.T2P_:;4.4:QGB;X:)9TQ:@L^B%U4E>I,H:H$]RBM!].8
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MG@=6,TCUFD-2G[Q;KA^!6KAIYIC-[DGT_J:;^-W[]+/UYWF@69TD0?2X!O_
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M=O*)6>'()(JS 0RRGQEW*4D-Y=_D1-IP1+->BZ U)<8"+(5BWCS&8AP2Z']
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M$L.F/T- -J0XNN:!@Y4[E.Y<@2N)(?\PE+>'E5(!/BSQ0;U&NGP<J'*N!6"
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MKOM[K*9Q,G]U$4]U$1SKZ^ LFRJX4^]H\,OQSX_R^'("MWKS[FW_RR0>QF6
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M7&AXZKKU30/2G.0!G>R?ZFF&MX$70(:\<D(?#G/$@',ZI?5X>6OIT4%&U%N
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M<J8^P0)SP23%],$M)MUI%L+D)K@<9 4VJU0P Y%&4@H^!350A@Q<)EW@JEY
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M2<1X]T3T!_*6#J5+B!=4L<04"^M8,;9R.RSCNNSE]@=[%1U4B[U[/S@$:WD
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M\>%P.Y0TEZ,NQ++Z,AM]#K#4I1!I<D5L'U]UC]'V3O >+> %C(CL.'H"ICF
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M_S#%2 K7Q*E""GC[7Y@CP9;OUBQNX9Q2-%K1C5C?W, Y$T:'O#/,6].B@4.
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M5)SXR-"!$-4E^*)M!_)_V JYC/92<X<%]B'8]1'[9A_IQ)*_ 5!+ 0(4 Q0
M   ( &"#6U:\(2WK%10  +)W   .              "  0    !D,S<R,3DU
M9#AK+FAT;5!+ 0(4 Q0    ( &"#6U9O]OA>!10  .9G   1
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E,#(S,#(R,5]P<F4N>&UL4$L%!@     &  8 ?P$  &]Y      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
